The Japan TimesAlzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways. https://www.japantimes.co.jp/news/2025/12/12/world/science-health/alzheimers-trials-shift-approach/?utm_medium=Social&utm_source=mastodon #worldnews #sciencehealth #aging #dementia #alzheimer039s #pharmaceuticals #medicine #eisai #novonordisk
A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals #eisai #health
SydneyJimEach school began with a teacher who adapted what they learned. That’s why we have so many schools. In #Japan alone:
#Eisai studied #Chan in China, came back & founded #Japanese #RinzaiZen.
#Dōgen also went to China, studied Caodong (#Sōtō) & brought it back, reshaping it for #Japan.
#Shinran studied #Tendai, left it, & founded #JōdoShinshū.
#Nichiren followed the #LotusSūtra above all, creating his own movement. (4/10)
#Eisai studied #Chan in China, came back & founded #Japanese #RinzaiZen.
#Dōgen also went to China, studied Caodong (#Sōtō) & brought it back, reshaping it for #Japan.
#Shinran studied #Tendai, left it, & founded #JōdoShinshū.
#Nichiren followed the #LotusSūtra above all, creating his own movement. (4/10)
Shares of Asian pharmaceutical companies fell after U.S. President Donald Trump announced a plan to order a cut in U.S. prescription drug costs to bring them in line with other countries. https://www.japantimes.co.jp/business/2025/05/12/markets/asian-pharma-trump-drug-price/?utm_medium=Social&utm_source=mastodon #business #markets #medicine #pharmaceuticals #us #republicans #donaldtrump #trade #tariffs #astellas #onopharmaceutical #sumitomopharma #shionogi #eisai #takeda #astellaspharma #otsukaholdings
Tech Cybersecurity NieuwsFda keurt maandelijkse dosis leqembi goed voor alzheimerpatiënten https://www.trendingtech.news/trending-news/2025/01/51047/fda-keurt-maandelijkse-dosis-leqembi-goed-voor-alzheimerpati-nten #FDA #Alzheimer #Leqembi #Eisai #Biogen #Trending #News #Nieuws
Camellia Tea CeremonyEbisu-jinja was established by Myōan Eisai (明菴栄西) in 1202 to act as guardian for Kennin-ji (then being built), and to thank the god Ebisu for saving him from a storm when returning from the mainland.
Eisai is credited with bringing the Rinzai school of Zen and the tradition of tea-drinking to Japan.
Japan's health ministry on Tuesday approved the production and sale of a new medicine for ALS, raising hopes among patients. https://www.japantimes.co.jp/news/2024/09/24/japan/science-health/japan-new-als-drug-approve/ #japan #sciencehealth #als #eisai #mecobalamin
Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain
Britain's medicine regulator said Thursday that it approved a novel Alzheimer's drug developed jointly by Japanese drugmaker Eisai and U.S. partner Biogen. https://www.japantimes.co.jp/news/2024/08/23/japan/britain-eisai-drug/ #japan #eisai #alzheimers #drugs #uk
EURACTIV HealthEuropean Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
